In this article we will discuss Elotuzumab (Dosage Overview). So, let’s get started.
Elotuzumab is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
The recommended dosage of Elotuzumab is 10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks thereafter in conjunction with the recommended dosing of lenalidomide and low-dose dexamethasone as described below. Continue treatment until disease progression or unacceptable toxicity.
Patients must be premedicated before each dose of Elotuzumab.
Administer dexamethasone as follows:
On days that Elotuzumab is administered, give dexamethasone 28 mg orally between 3 and 24 hours before Elotuzumab plus 8 mg intravenously between 45 and 90 minutes before Elotuzumab.
On days that Elotuzumab is not administered but a dose of dexamethasone is scheduled (Days 8 and 22 of cycle 3 and all subsequent cycles), give 40 mg orally.
When Elotuzumab is used in combination with lenalidomide, divide dexamethasone into an oral and intravenous dose.
In addition to dexamethasone, complete administration of the following medications 45 to 90 minutes prior to Elotuzumab infusion:
H1 blocker: diphenhydramine (25-50 mg orally or intravenously) or equivalent H1 blocker.
H2 blocker: ranitidine (50 mg intravenously or 150 mg orally) or equivalent H2 blocker
Acetaminophen (650-1000 mg orally).